Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Overview of attention for article published in Journal of Hematology & Oncology, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 2 news outlets

twitter: 3 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 17 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,548 followers.

We're one step 👣 closer to treating #MultipleMyeloma! Drs. Ja Min Byun, Youngil Koh & team at @SNUnow conducted a Phase II trial of DARA-DCEP to develop a therapeutic approach for #extramedullary multiple myeloma. 👇 Check out the results! https://t.c

31 Oct 2022

Reply Repost Favourite

https://t.co/FKhb32gZC9

30 Oct 2022

Reply Repost Favourite

New article: Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease https://t.co/nxDjCZ8UTo #MMSM #MultipleMyeloma #hematology https://t.co/LTrqdZOmg1

24 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.